KDR and neoplasm: Our results showingincreased dose and shortened surgical window overcoming putative negative (or negligible)post-surgical impact on overall survival could warrant consideration in clinical neoadjuvant trialswith VEGFR TKIs, where parameters of tumor dosing and tumor size are still being investigated interms of assessing overall benefit (Kroon et al, 2013).